128 related articles for article (PubMed ID: 23671017)
61. Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors.
Hu S; Xie G; Zhang DX; Davis C; Long W; Hu Y; Wang F; Kang X; Tan F; Ding L; Wang Y
Bioorg Med Chem Lett; 2012 Oct; 22(19):6301-5. PubMed ID: 22959248
[TBL] [Abstract][Full Text] [Related]
62. Pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as novel anti-proliferative agents: parallel synthesis for lead optimization of amide region.
Gopalsamy A; Yang H; Ellingboe JW; Tsou HR; Zhang N; Honores E; Powell D; Miranda M; McGinnis JP; Rabindran SK
Bioorg Med Chem Lett; 2005 Mar; 15(6):1591-4. PubMed ID: 15745803
[TBL] [Abstract][Full Text] [Related]
63. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.
Chen CT; Hsu JT; Lin WH; Lu CT; Yen SC; Hsu T; Huang YL; Song JS; Chen CH; Chou LH; Yen KJ; Chen CP; Kuo PC; Huang CL; Liu HE; Chao YS; Yeh TK; Jiaang WT
Eur J Med Chem; 2015 Jul; 100():151-61. PubMed ID: 26081023
[TBL] [Abstract][Full Text] [Related]
64. A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.
Lee W; Ortwine DF; Bergeron P; Lau K; Lin L; Malek S; Nonomiya J; Pei Z; Robarge KD; Schmidt S; Sideris S; Lyssikatos JP
Bioorg Med Chem Lett; 2013 Sep; 23(18):5097-104. PubMed ID: 23932790
[TBL] [Abstract][Full Text] [Related]
65. Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase.
Goldstein DM; Soth M; Gabriel T; Dewdney N; Kuglstatter A; Arzeno H; Chen J; Bingenheimer W; Dalrymple SA; Dunn J; Farrell R; Frauchiger S; La Fargue J; Ghate M; Graves B; Hill RJ; Li F; Litman R; Loe B; McIntosh J; McWeeney D; Papp E; Park J; Reese HF; Roberts RT; Rotstein D; San Pablo B; Sarma K; Stahl M; Sung ML; Suttman RT; Sjogren EB; Tan Y; Trejo A; Welch M; Weller P; Wong BR; Zecic H
J Med Chem; 2011 Apr; 54(7):2255-65. PubMed ID: 21375264
[TBL] [Abstract][Full Text] [Related]
66. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
[TBL] [Abstract][Full Text] [Related]
67. Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
Salerno S; Marini AM; Fornaciari G; Simorini F; La Motta C; Taliani S; Sartini S; Da Settimo F; García-Argáez AN; Gia O; Cosconati S; Novellino E; D'Ocon P; Fioravanti A; Orlandi P; Bocci G; Dalla Via L
Eur J Med Chem; 2015 Oct; 103():29-43. PubMed ID: 26318056
[TBL] [Abstract][Full Text] [Related]
68. Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor.
Kang GA; Lee M; Song D; Lee HK; Ahn S; Park CH; Lee CO; Yun CS; Jung H; Kim P; Ha JD; Cho SY; Kim HR; Hwang JY
Bioorg Med Chem Lett; 2015 Sep; 25(18):3992-8. PubMed ID: 26235945
[TBL] [Abstract][Full Text] [Related]
69. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.
Addie M; Ballard P; Buttar D; Crafter C; Currie G; Davies BR; Debreczeni J; Dry H; Dudley P; Greenwood R; Johnson PD; Kettle JG; Lane C; Lamont G; Leach A; Luke RW; Morris J; Ogilvie D; Page K; Pass M; Pearson S; Ruston L
J Med Chem; 2013 Mar; 56(5):2059-73. PubMed ID: 23394218
[TBL] [Abstract][Full Text] [Related]
70. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.
Toogood PL; Harvey PJ; Repine JT; Sheehan DJ; VanderWel SN; Zhou H; Keller PR; McNamara DJ; Sherry D; Zhu T; Brodfuehrer J; Choi C; Barvian MR; Fry DW
J Med Chem; 2005 Apr; 48(7):2388-406. PubMed ID: 15801831
[TBL] [Abstract][Full Text] [Related]
71. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.
Nowak P; Cole DC; Brooijmans N; Bursavich MG; Curran KJ; Ellingboe JW; Gibbons JJ; Hollander I; Hu Y; Kaplan J; Malwitz DJ; Toral-Barza L; Verheijen JC; Zask A; Zhang WG; Yu K
J Med Chem; 2009 Nov; 52(22):7081-9. PubMed ID: 19848404
[TBL] [Abstract][Full Text] [Related]
72. Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors.
Pasquier B; El-Ahmad Y; Filoche-Rommé B; Dureuil C; Fassy F; Abecassis PY; Mathieu M; Bertrand T; Benard T; Barrière C; El Batti S; Letallec JP; Sonnefraud V; Brollo M; Delbarre L; Loyau V; Pilorge F; Bertin L; Richepin P; Arigon J; Labrosse JR; Clément J; Durand F; Combet R; Perraut P; Leroy V; Gay F; Lefrançois D; Bretin F; Marquette JP; Michot N; Caron A; Castell C; Schio L; McCort G; Goulaouic H; Garcia-Echeverria C; Ronan B
J Med Chem; 2015 Jan; 58(1):376-400. PubMed ID: 25402320
[TBL] [Abstract][Full Text] [Related]
73. Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.
Defaux J; Antoine M; Logé C; Le Borgne M; Schuster T; Seipelt I; Aicher B; Teifel M; Günther E; Gerlach M; Marchand P
Bioorg Med Chem Lett; 2014 Aug; 24(16):3748-52. PubMed ID: 25022204
[TBL] [Abstract][Full Text] [Related]
74. Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates.
Sirvent JA; Lücking U
ChemMedChem; 2017 Apr; 12(7):487-501. PubMed ID: 28221724
[TBL] [Abstract][Full Text] [Related]
75. Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
Mallinger A; Schiemann K; Rink C; Stieber F; Calderini M; Crumpler S; Stubbs M; Adeniji-Popoola O; Poeschke O; Busch M; Czodrowski P; Musil D; Schwarz D; Ortiz-Ruiz MJ; Schneider R; Thai C; Valenti M; de Haven Brandon A; Burke R; Workman P; Dale T; Wienke D; Clarke PA; Esdar C; Raynaud FI; Eccles SA; Rohdich F; Blagg J
J Med Chem; 2016 Feb; 59(3):1078-101. PubMed ID: 26796641
[TBL] [Abstract][Full Text] [Related]
76. Application of sulfoximines in medicinal chemistry from 2013 to 2020.
Han Y; Xing K; Zhang J; Tong T; Shi Y; Cao H; Yu H; Zhang Y; Liu D; Zhao L
Eur J Med Chem; 2021 Jan; 209():112885. PubMed ID: 33227576
[TBL] [Abstract][Full Text] [Related]
77. Engineering Selectivity for Reduced Toxicity of Bacterial Kinase Inhibitors Using Structure-Guided Medicinal Chemistry.
Wlodarchak N; Feltenberger JB; Ye Z; Beczkiewicz J; Procknow R; Yan G; King TM; Golden JE; Striker R
ACS Med Chem Lett; 2021 Feb; 12(2):228-235. PubMed ID: 35035774
[TBL] [Abstract][Full Text] [Related]
78. [Experimental studies on biological activity of 2-oxy-6-aminopyrimidine (cytosine)].
GRAUL EH; PATZSCHKE K
Arzneimittelforschung; 1953 Mar; 3(3):212-5. PubMed ID: 13066355
[No Abstract] [Full Text] [Related]
79. Sulfoximines: a neglected opportunity in medicinal chemistry.
Lücking U
Angew Chem Int Ed Engl; 2013 Sep; 52(36):9399-408. PubMed ID: 23934828
[TBL] [Abstract][Full Text] [Related]
80. Synthesis of Pyrazolesulfoximines Using α-Diazosulfoximines with Alkynes.
Zhong Z; Ma TK; White AJP; Bull JA
Org Lett; 2024 Feb; 26(6):1178-1183. PubMed ID: 38306458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
